Improving Pain Management and Decreasing LOS After Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA)
Pain

About this trial
This is an interventional treatment trial for Pain focused on measuring pain, length of stay, peri-operative, THA, TKA
Eligibility Criteria
Inclusion Criteria:
- Adults 50 to 80 years, inclusive
- Planned primary THA or TKA
- Expressed willingness to be discharged the same day of surgery if condition allows
American Society of Anesthesiologists (ASA) physical classes I - III
- ASA I: A normal healthy patient. Example: Fit, nonobese (BMI under 30), a nonsmoking patient with good exercise tolerance.
- ASA II: A patient with a mild systemic disease. Example: Patient with no functional limitations and a well-controlled disease (e.g., treated hypertension, obesity with BMI under 35, frequent social drinker or is a cigarette smoker).
- ASA III: A patient with a severe systemic disease that is not life-threatening. Example: Patient with some functional limitation as a result of disease (e.g., poorly treated hypertension or diabetes, morbid obesity, chronic renal failure, a bronchospastic disease with intermittent exacerbation, stable angina, implanted pacemaker).
- Patients who are English competent.
Exclusion Criteria:
- Opioid tolerant (> 50 mg oral morphine milligram equivalents (MMEs) daily)
- Current IV drug abuse
- History of alcoholism
- History of severe renal impairment
- History of severe hepatic impairment
- Dependent on supplemental oxygen at home
- Pregnant
- Incarcerated
- Patient unable to provide informed consent
- Patients undergoing bilateral TKA, THA
- Patient undergoing unicompartmental knee arthroplasty (UKA)
- Patients undergoing other concurrent surgery
- Patients with a history of allergy to any drugs in the study.
Sites / Locations
- The CORE Institute Specialty HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Treatment
Control
One dose of sufentanil 30 mcg sublingual will be given pre-operatively when entering the operating room and one dose post-operatively in the PACU in addition to standard of care pain management.
A multimodal approach to analgesia will be used in all subjects in the perioperative setting and will be used in both the control and treatment groups. Intraoperative dosing of opioids will be based on the anesthesiologist's clinical judgement related to the pain and hemodynamic response to surgical stimuli and on an as needed basis in the PACU. Administration of opioids in the PACU will be in response to moderate-to-severe pain.